secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2026-06-04T12:30:11+00:00
Accession:  0001437749-26-019478
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru enters clinical supply deal with Novo Nordisk for Phase 2b combo study of enobosarm + Wegovy
--------------------------------------------------------------------------------

- Veru sponsors Phase 2b PLATEAU study testing enobosarm + Wegovy in older adults with obesity on GLP-1 therapy.
- Novo Nordisk supplies Wegovy at no cost; Veru retains full global rights to enobosarm.
- Veru grants Novo Nordisk right of first negotiation if Veru develops enobosarm combo with any Novo GLP-1 product.
- Veru provides trial design and safety data insights; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/0001437749-26-019478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-019478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer